Serum Biomarkers and the Prognosis of AMI Patients

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2013 May 8

PMID 23649322

Citations 13

Authors

S Wei

L Mao

B Liu

L Zhong

Affiliations

Soon will be listed here.

Abstract

Background: It has been proven that serum lactate dehydrogenase (LDH) and total bilirubin (TB) increase during acute myocardial infarction (AMI). However, how they influence the prognosis of AMI patients is still not completely known.

Methods: A total of 239 patients diagnosed with AMI and admitted to the Fourth Clinical Hospital of Harbin Medical University, between 2007 and 2008, were enrolled in this study. All the patients had not undergone primary percutaneous coronary intervention (PCI) because the time window (24 h) was missed. They all underwent PCI 1 week after the onset of symptoms. Serum high-sensitivity C-reactive protein (hs-CRP), TB, LDH, and other biomarkers were determined between 24 and 48 h of symptom onset. All of the patients were followed up for an average of 3.2±0.4 years for occurrence of major adverse cardiac events (MACE).

Results: Patients with MACE had significantly higher levels of hs-CRP, LDH, cystatin C, uric acid, a higher ratio of LDH and TB (LDH/TB), and a lower level of TB: 8.48±3.84 vs. 2.13±1.32 μmol/l, p<0.01; 1,355.8±654.3 vs. 1,151.7±415.4 U/l, p<0.01; 1.69±0.76 vs. 1.00±0.46 mg/l, p<0.01; 419.6±109.2 vs. 343.2±108.2 μmol/l, p<0.01 and 141.1±46.2 vs. 61.2±26.5, p<0.01; 18.3±6.7 vs. 14.8±6.6 mg/l, p<0.01, respectively. In the multivariate COX analysis, LDH, cystatin C, and LDH/TB were significantly associated with the prognosis of these patients.

Conclusions: Patients under higher oxidative stress tend to have more MACE. LDH, cystatin C, and LDH/TB are strongly related to the prognosis of AMI patients undergoing elective PCI.

Citing Articles

The predictive value of serum fibrinogen and platelet distribution width for long-term cardiac death in acute myocardial infarction patients.

Zhou Z, Hu C, Gao M, Jin X, Chen Y, Wang D J Thorac Dis. 2024; 16(8):5073-5085.

PMID: 39268112 PMC: 11388258. DOI: 10.21037/jtd-24-204.

Abnormal expression of circ_0013958 in patients with acute myocardial infarction (AMI) and its influence on prognosis.

Sun F, Zou S, Li X, Liu X J Cardiothorac Surg. 2024; 19(1):517.

PMID: 39243066 PMC: 11378589. DOI: 10.1186/s13019-024-03036-8.

Differential gene expression patterns in ST-elevation Myocardial Infarction and Non-ST-elevation Myocardial Infarction.

Elahimanesh M, Shokri N, Mahdinia E, Mohammadi P, Parvaz N, Najafi M Sci Rep. 2024; 14(1):3424.

PMID: 38341440 PMC: 10858964. DOI: 10.1038/s41598-024-54086-w.

Predictive values of bilirubin for in-hospital adverse events in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention.

Ying C, Liu C, Guo D, Du Z, Wei Y Clinics (Sao Paulo). 2023; 78:100306.

PMID: 37949037 PMC: 10661652. DOI: 10.1016/j.clinsp.2023.100306.

Correlation Between GDF11 Serum Levels, Severity of Coronary Artery Lesions, and the Prognosis of Patients with ST-segment Elevation Myocardial Infarction.

Xu B, Chen K, Su W, Liu Y, Sheng Y, Ye T J Cardiovasc Transl Res. 2023; 16(4):938-947.

PMID: 36749564 DOI: 10.1007/s12265-023-10358-w.

References

Horsfall L, Nazareth I, Petersen I . Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation. 2012; 126(22):2556-64. DOI: 10.1161/CIRCULATIONAHA.112.114066. View

Gao C, Zhong L, Gao Y, Li X, Zhang M, Wei S . Cystatin C levels are associated with the prognosis of systolic heart failure patients. Arch Cardiovasc Dis. 2011; 104(11):565-71. DOI: 10.1016/j.acvd.2011.08.003. View

Spoon D, Lerman A, Rule A, Prasad A, Lennon R, Holmes D . The association of serum uric acid levels with outcomes following percutaneous coronary intervention. J Interv Cardiol. 2010; 23(3):277-83. DOI: 10.1111/j.1540-8183.2010.00555.x. View

Kiyosue A, Hirata Y, Ando J, Fujita H, Morita T, Takahashi M . Plasma cystatin C concentration reflects the severity of coronary artery disease in patients without chronic kidney disease. Circ J. 2010; 74(11):2441-7. DOI: 10.1253/circj.cj-10-0158. View

Damman K, van der Harst P, Smilde T, Voors A, Navis G, Van Veldhuisen D . Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart. 2011; 98(4):319-24. DOI: 10.1136/heartjnl-2011-300692. View

Gach O, Legrand V, Biessaux Y, Chapelle J, Vanbelle S, Pierard L . Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol. 2007; 99(1):31-5. DOI: 10.1016/j.amjcard.2006.07.059. View

Wei S, Zhong L, Chen S, Li X . The status of coronary artery lesions in patients with conduction disturbance. J Cardiovasc Med (Hagerstown). 2011; 12(10):709-13. DOI: 10.2459/JCM.0b013e328349187c. View

Chow S, OBarr S, Peng J, Chew E, Pak F, Quist R . Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study. Circ Heart Fail. 2011; 4(4):450-5. DOI: 10.1161/CIRCHEARTFAILURE.110.958066. View

Ogita M, Sakakura K, Nakamura T, Funayama H, Wada H, Naito R . Association between deteriorated renal function and long-term clinical outcomes after percutaneous coronary intervention. Heart Vessels. 2011; 27(5):460-7. DOI: 10.1007/s00380-011-0177-6. View

10.

Koc M, Batur M, Karaarslan O, Abali G . Clinical utility of serum cystatin C in predicting coronary artery disease. Cardiol J. 2010; 17(4):374-80. View

11.

Zhao C, Yang L, Mao L, Zhong L, Li X, Wei S . Cystatin C associates with the prediction of in-stent restenosis among patients receiving stent implantation: results of the 1-year follow-up. Coron Artery Dis. 2013; 24(5):357-60. DOI: 10.1097/MCA.0b013e328361b3a4. View

12.

Okuhara K, Kisaka T, Ozono R, Kurisu S, Inoue I, Soga J . Change in bilirubin level following acute myocardial infarction is an index for heme oxygenase activation. South Med J. 2010; 103(9):876-81. DOI: 10.1097/SMJ.0b013e3181eac06a. View

13.

Schnyder G, Flammer Y, Roffi M, Pin R, Hess O . Plasma homocysteine levels and late outcome after coronary angioplasty. J Am Coll Cardiol. 2002; 40(10):1769-76. DOI: 10.1016/s0735-1097(02)02481-6. View

14.

Ferguson M, Waikar S . Established and emerging markers of kidney function. Clin Chem. 2012; 58(4):680-9. PMC: 5136473. DOI: 10.1373/clinchem.2011.167494. View

15.

Calan M, Calan O, Gonen M, Bilgir F, Kebapcilar L, Kulac E . Examination of adhesion molecules, homocysteine and hs-CRP in patients with polygenic hypercholesterolemia and isolated hypertriglyceridemia. Intern Med. 2011; 50(15):1529-35. DOI: 10.2169/internalmedicine.50.4297. View

16.

Spinler S, Hilleman D, Cheng J, Howard P, Mauro V, Lopez L . New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines. Ann Pharmacother. 2001; 35(5):589-617. DOI: 10.1345/aph.10319. View

17.

Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y . Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation. 2012; 126(5):598-603. DOI: 10.1161/CIRCULATIONAHA.112.105775. View

18.

Ford A, Garrido G, Beer C, Lautenschlager N, Arnolda L, Flicker L . Homocysteine, grey matter and cognitive function in adults with cardiovascular disease. PLoS One. 2012; 7(3):e33345. PMC: 3296688. DOI: 10.1371/journal.pone.0033345. View

19.

Vitek L . The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012; 3:55. PMC: 3318228. DOI: 10.3389/fphar.2012.00055. View

20.

Iwataki M, Takeuchi M, Otani K, Kuwaki H, Haruki N, Yoshitani H . Measurement of left atrial volume from transthoracic three-dimensional echocardiographic datasets using the biplane Simpson's technique. J Am Soc Echocardiogr. 2012; 25(12):1319-26. DOI: 10.1016/j.echo.2012.08.017. View